Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 29, 2017
Pharmacy Choice - News - Front Page Healthcare News - March 29, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/29/17 - A Nation Divided on Insurance, but Medicare Works Just Fine
This past week, as the day approached for the momentous vote to replace the Affordable Care Act with the so-called American Health Care Act, it became blindingly obvious that this is exactly what President Trump had done to House Speaker Ryan. Uninterested in the grinding work of producing coherent legislation not for nothing is the process comp
3/29/17 - Acorda Announces Long-Term Safety Data for CVT-301
Acorda Therapeutics, Inc. today announced results from two ongoing, long-term safety studies of CVT-301 in people with Parkinson s that showed no differences in pulmonary function between the group receiving CVT-301 and an observational control group. These results are consistent with previously reported data from Phase 2 b and Phase 3 clinical
3/29/17 - Advanced Urology Associates Announces Designation as a UroLift Center of Excellence Led by Dr. Gregory J. Andros
The designation recognizes that Dr. Andros has demonstrated a commitment to exemplary care for men suffering from urinary tract symptoms and has achieved a high level of training and experience with the UroLift System. Dr. Andros is among the first ten physicians in the nation and the first in the Great Lakes Region to receive a UroLift Center of E
3/29/17 - Agency Forms Submitted for OMB Review, Request for Comments
Summary: In accordance with the Paperwork Reduction Act of 1995, the Railroad Retirement Board is forwarding an Information Collection Request to the Office of Information and Regulatory Affairs, Office of Management and Budget. Our ICR describes the information we seek to collect from the public. Review and approval by OIRA ensures that we impose.
3/29/17 - Allergan, Paratek hit late-stage acne goals, prep for sarecycline NDA [Syrian Arab News Agency]
Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for their investigational med sarecycline. The pair will now seek an FDA NDA in the second half of the year after the two replicative late-stage tests that saw the med outdo placebo in treating inflammatory acne lesions in subjects with mode
3/29/17 - Amend Surgical Signs Exclusive License Agreement with University of Florida Research Foundation for Biomimetic Bone
By a News Reporter-Staff News Editor at Biotech Week Amend Surgical, Inc., a medical device company focused on enhancing the regenerative capacity of bone replacement products, announced an exclusive agreement with The University of Florida Research Foundation to license patents for the development of Biomimetic Bone, a novel artificial bone subs
3/29/17 - AP Top Health News at 2:45 a.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - AP Top Health News at 8:05 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - AP Top Health News at 8:16 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - APCER Life Sciences Launches Quality Assurance Auditing and Consultancy Services
New offering meets growing demand for expertise in compliance across pharmaceutical companies' clinical and post-marketing ecosystem LONDON, March 29, 2017 APCER Life Sciences, the truly global provider of safety, medical, regulatory and technology services, announced today that it will now offer Quality Assurance Auditing as a stand-alone servic
3/29/17 - ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer
ARMO BioSciences, Inc., a clinical-stage immuno-oncology company, announced that the first patient has been dosed in the Company's international Phase 3 pivotal clinical trial to evaluate its lead investigational immuno-oncology drug AM0010 in combination with FOLFOX as second-line treatment for patients with advanced pancreatic cancer.
3/29/17 - AstraZeneca Gets Priority Review By US Of LYNPARZA For Ovarian Cancer
LONDON- AstraZeneca PLC's new drug application for LYNPARZA tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting has been accepted for priority review by the US Food& Drug Administration- with a decision expected in the third quarter 2017.. In clinical trials, LYNPARZA demonstrated a median Progression
3/29/17 - Bharat Book Bureau: Global Over-the-Counter (OTC) Drugs and Dietary Supplements Markets
The global market for over the counter drugs and dietary supplements reached $164.7 billion in 2016 and should reach $220.8 billion in 2021, with a compound annual growth rate of 6.0%. The study goal of this report is to understand the OTC drugs and dietary supplement market and provide five-year forecasts for the same. The objective of the study i
3/29/17 - Bharat Book Bureau: Infectious Disease Drugs The Chinese Market
The Chinese infectious disease drug market is big, fast-growing and dominated by brands from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions that look for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehe
3/29/17 - British new lung cancer drug wins approval in China [Philippines News Agency]
The London stock market listed company AstraZeneca Monday announced that the China Food and Drug Administration has granted marketing authorization for its lung cancer pill Tagrisso in China. Tagrisso is designed for the treatment of adult patients with certain genetic mutations, which is the first AstraZeneca medicine approved under the CFDA's...
3/29/17 - Center Point Clinical Services' Studies Show That Pharmacist-led Interventions Increase Clinical Trial Patient Medication Adherence and Compliance and Provide Robust Study Data
Center Point Clinical Services, creator of the world's first Siteless CRO platform, announced today study results presented in two separate posters at the Academy of Managed Care Pharmacy,# AMCP2017, Managed Care and Specialty Pharmacy annual meeting in Denver, Colorado. Joe Martinez, CEO of Center Point Clinical Services and the lead author of bot
3/29/17 - Credence Research: Global Ultrasound Devices Market Size, Share, Growth, Strategies, Analysis and Forecast to 2022 - Credence Research
The latest market report published by Credence Research, Inc. "Global Ultrasound Devices Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016- 2022," the ultrasound devices market was valued at USD 5,524.5 Mn in 2015, and is expected to reach USD 7,805.9 Mn by 2022, expanding at a CAGR of 5.02% from 2016 to 2022.. Browse t
3/29/17 - Credence Research: RECENT RELEASE : GLOBAL MATERNITY COLOR ULTRASOUND DIAGNOSTIC EQUIPMENT MARKET, SIZE, SHARE REGIONAL OUTLOOK 2017 ACUTE MARKET REPORTS
This report studies sales of Maternity Color Ultrasound Diagnostic Equipment in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering. With Four-dimensional Color Doppler Ultrasound. Without Four-dimensional Color Doppler Ultrasound.
3/29/17 - EDITORIAL: Health care battle lives on [Waterloo-Cedar Falls Courier, Iowa]
March 28 Democrats may rejoice about the Republican Party's civil war that doomed its ill-conceived attempt to "repeal and replace" the Affordable Care Act, but the battle over the national health care program isn't over. "We're going to be living with' Obamacare' for the foreseeable future," said House Speaker Paul Ryan, R- Wis., after pulling
3/29/17 - EDITORIAL: Please, Gov. Brownback sign the Medicaid expansion bill [The Kansas City Star]
March 29 More than 140,000 Kansans are tantalizingly close to qualifying for Medicaid, the federal-state program providing health insurance coverage for poor and low-income Americans. On Tuesday, the Kansas Senate joined the House and voted to expand Medicaid. Lawmakers in those states know the federal government will eventually pay 90 percent of
3/29/17 - Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of Materials and Communications to Healthcare Professionals Regarding Abuse-Deterrent Properties of ARYMO? ER via Intranasal Route
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the U.S. Food and Drug Administration does not object to Egalet's distribution of promotional materials and communications to healthcare professionals...
3/29/17 - Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
TOKYO, Mar 29, 2017 Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme inhibitor elenbecestat in patients with early Alzheimer's disease. The Phase III clinical trial program for elenbecestat consists of two global
3/29/17 - EU recommends withdrawing drugs approved on unreliable data [Tehran Times (Iran)]
The European Medicines Agency concluded that data from bioequivalence studies conducted by Micro Therapeutic Research Labs at its two sites in Tamil Nadu, between June 2012 and June 2016, are unreliable and cannot be accepted as a basis for marketing authorisation in the EU.
3/29/17 - Failed trial pushes Foamix down 40% [Globes, Tel Aviv, Israel]
March 29 The share of Foamix Pharmaceuticals Ltd., which develops foam-based drugs, yesterday lost 40% of its value, following unsatisfactory results of the company's clinical trials of its leading product, designed to treat acne. Foamix's market cap is now $197 million, The company has $130 million in cash, which it raised in three financing rou
3/29/17 - Failed trial pushes Foamix down 40% [Sudan Tribune]
The share of Foamix Pharmaceuticals Ltd., which develops foam-based drugs, yesterday lost 40% of its value, following unsatisfactory results of the company`s clinical trials of its leading product, designed to treat acne. Foamix`s market cap is now $197 million, The company has $130 million in cash, which it raised in three financing rounds since i
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415